Januritine S Combi Tablet 50/1000mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daiwon Pharmaceutical Co., Ltd.
MFDS item code 201505585 · Approved 2015.08.12
This product's status changed to Expired on 2025.08.12. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication contains both sitagliptin and metformin, used to help patients with type 2 diabetes control their blood sugar levels. When taken along with dietary management and exercise therapy, it supports more stable blood sugar management. Regular use is effective in improving blood glucose levels for diabetes management. This treatment also helps in preventing complications. This medication is recommended for the overall health maintenance of patients.
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, Contraindications). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, General precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Contraindications).
This medication contains sitagliptin and metformin and is used for the treatment of type 2 diabetes. Firstly, while taking this medication, serious allergic reactions may occur, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck appear, immediate discontinuation and consultation with a doctor are necessary. Additionally, this medication may cause acute pancreatitis, so if symptoms like abdominal pain, vomiting, or nausea arise, immediate medical attention should be sought. Patients with very poor kidney function or severe infections, dehydration, or heart failure may be at risk if taking this medication, and it should not be administered. Before and after tests using radiographic iodine contrast agents, this medication should be temporarily discontinued due to the risk of kidney damage, and may only be resumed once normal kidney function is confirmed. Women who are pregnant or may become pregnant, as well as nursing mothers, should not use this medication. While taking this medication, symptoms of hypoglycemia may occur, so especially when taken in conjunction with other hypoglycemic agents or insulin, careful monitoring of blood sugar changes is required. Furthermore, due to the metformin component, this medication may cause a rare but serious metabolic disorder known as lactic acidosis, so regular checks of kidney function and vitamin B12 levels should be performed. Excessive alcohol consumption, acute illnesses, or perioperative periods may require temporary discontinuation of this medication, with resumption once conditions stabilize. During the use of this medication, it is important to maintain a consistent diet and exercise regimen and to have regular blood sugar and kidney function tests. Finally, immediate consultation with healthcare professionals is necessary if any abnormal symptoms or discomfort arise while taking this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air ingress, preferably at room temperature between 1 to 30 degrees Celsius. This storage method helps to maintain the medication's effectiveness and safety.
Dark red oval film-coated tablet
28 tablets (14 tablets/PTPX2), 56 tablets (14 tablets/PTPX4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daiwon Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.